ONO Pharmaceutical Co ((OPHLF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: ONO Pharmaceutical Co. is conducting a Phase IIa clinical study titled A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Fibromyalgia. The study aims to assess the efficacy and safety of ONO-1110 in treating fibromyalgia, a chronic condition characterized by widespread pain, which could significantly impact patient quality of life.
Intervention/Treatment: The study tests ONO-1110, an experimental drug administered as a daily tablet, against a placebo. The purpose is to determine if ONO-1110 can effectively alleviate symptoms of fibromyalgia.
Study Design: This is an interventional study with a randomized, parallel assignment. It employs a double-blind approach, meaning neither participants nor investigators know who receives the actual drug or placebo. The primary goal is treatment-focused, aiming to evaluate ONO-1110’s therapeutic potential.
Study Timeline: The study began on December 22, 2024, with a recent update on September 19, 2025. These dates are crucial as they indicate the study’s progress and ongoing recruitment status.
Market Implications: The successful development of ONO-1110 could enhance ONO Pharmaceutical’s market position, potentially boosting its stock performance. As fibromyalgia treatments are in demand, this study’s progress may influence investor sentiment positively, especially if results show significant efficacy. Competitors in the fibromyalgia treatment space will likely monitor these developments closely.
The study is currently recruiting, with further details available on the ClinicalTrials portal.